August 1, 2017
Eligible Patients to be Directed to Epizyme’s Ongoing Phase 2 Clinical Trial of Tazemetostat in Follicular Lymphoma and Diffuse Large B-cell Lymphoma THE WOODLANDS, Texas and CAMBRIDGE, Mass. (August 1, 2017) – Epizyme, Inc. (NASDAQ: EPZM), a clinical-stage biopharmaceutical company creating novel epigenetic therapies, and US Oncology Research, one of the nation’s largest networks of […]
Read MoreJune 23, 2017
Intensive workshop provided resources, expertise to help practices succeed with the Oncology Care Model, MIPS and other alternative payment programs The Woodlands, Texas (June 23, 2017) — The US Oncology Network (The Network) hosted its second annual boot camp last month in Dallas, focusing on various value-based care delivery and reimbursement models. The intensive two-day […]
Read MoreJune 14, 2017
Expanded agreement enhances Value Pathways, providing physicians access to the most recent evidence available for five additional disease states The Woodlands, Texas (June 14, 2017)— McKesson and The US Oncology Network (The Network) have expanded their agreement with the National Comprehensive Cancer Network® (NCCN®), adding five additional disease states to Value Pathways powered by NCCN. […]
Read MoreJune 13, 2017
New facility developed by Ryan Companies US, Inc. offers leading-edge cancer care to growing East Valley region Tempe, Ariz. (June 13, 2017) — Arizona Oncology’s new state-of-the-art cancer treatment center, located at the Arizona State University Research Park (ASURP), is now open and offering the latest cancer treatment services available to patients in Phoenix and […]
Read MoreJune 8, 2017
New clinic enhances world-class research program by strengthening Phase I capabilities Fairfax, Va. (June 8, 2017) — There is good news today for patients in Northern Virginia who are battling cancer, as well as those who may face the disease in the future. Virginia Cancer Specialists (VCS), Northern Virginia’s premier cancer care and research center […]
Read MoreMay 31, 2017
Approximately 40 abstracts accepted for presentation, highlighting the importance of community-based cancer research in developing new and novel cancer fighting therapies in areas like hematology, breast cancer, and immuno-oncology Debra Patt, MD, MBA, MPH, to speak during an Educational Session on creating an informatics-driven oncology practice The Woodlands, Texas (May 31, 2017) – Community oncologists […]
Read MoreMay 12, 2017
The Woodlands, Texas (May 12, 2017) — McKesson Corporation has played a significant role in the recent approval of ZEJULATM (niraparib). Approximately ten practices affiliated with US Oncology Research, one of the largest community-based oncology research programs in the United States supported by McKesson, participated in the clinical trial that led to approval by the U.S. Food […]
Read MoreApril 27, 2017
Presentations will focus on innovative solutions for community oncology success and cancer care delivery in today’s challenging environment The Woodlands, Texas (April 27, 2017) — Thought leaders from McKesson and The US Oncology Network (“The Network”) will play an important role in the upcoming 2017 Community Oncology Conference, the most comprehensive gathering in the country […]
Read MoreApril 25, 2017
Program reaches recruitment milestone while bringing novel treatments to community cancer centers The Woodlands, Texas (April 25, 2017) — US Oncology Research, one of the largest community-based oncology research programs in the United States, enrolled more than 2,900 subjects into clinical trials during the fiscal year ended March 31, 2017. The participation of these patients […]
Read MoreMarch 1, 2017
Practice with largest infusion treatment center in Delaware gains access to world-class treatments and enhances its cutting-edge research program Newark, Del. (March 1, 2017) – Medical Oncology Hematology Consultants (“MOHC”), the premier provider of advanced treatments for cancer and blood disorder patients in Delaware for more than 30 years, has joined The US Oncology Network […]
Read More
